Archives
-
Lysis Buffer and CRC Biomarker Evidence
2026-10-08
This overview separates the documented role of a lysis buffer in mouse genotyping from findings reported in a 2026 colorectal cancer transcriptomic study. It compares evidence strength, clarifies conceptual applications, and explains why a product description cannot validate a prognostic signature or establish clinical utility.
-
Angiotensin III: A Receptor-Centered RAAS Probe
2026-10-08
Angiotensin III is more than a downstream RAAS fragment: it is a context-dependent peptide for separating aldosterone, vascular, neural, and emerging spike-receptor binding signals. This article interprets the evidence around SKU A1043 while distinguishing established pharmacology from the hypothesis-generating findings of a 2025 study.
-
Multi-Omics Maps ARID1A-Linked Melanoma Resistance
2026-10-07
The reference study integrates signaling, transcriptional, protein-level, and network evidence to explain how ARID1A loss is associated with resistance to BRAF/MAPK inhibition in melanoma. Its main contribution is the identification of coordinated resistance circuitry involving MAPK1/3, JNK, PRKD1, JUN, NCK1, receptor tyrosine kinases, and immune-related protein changes.
-
Recombinant Human FGF-19 Product Overview
2026-10-07
Recombinant Human FGF-19 is a supplier-described, tag-free, lyophilized protein expressed in E. coli for conceptual research involving FGF19/FGFR4 endocrine signaling. No matched paper evidence was provided, so independent performance and application-specific conclusions cannot be established.
-
Sulfaphenazole: CYP2C9 and Antimicrobial Evidence
2026-10-06
Sulfaphenazole is studied as both a competitive CYP2C9 inhibitor and a sulfonamide with in vitro antimycobacterial activity. This overview compares the strongest supplied evidence, explains its research context, and defines the limits of extrapolating from biochemical, cellular, and supplier-reported findings to therapeutic use.
-
PreScission Protease (PSP): Product Overview
2026-10-06
PreScission Protease (PSP), SKU K1101, is described by APExBIO as a recombinant HRV 3C protease–GST fusion intended for conceptual use in affinity-tag removal from recombinant proteins. No matched peer-reviewed paper evidence was provided, so performance and applicability remain unverified here.
-
Novel FLCN Mutations and mRNA Rescue in BHD
2026-10-05
A 2026 study identified two clinically relevant FLCN variants in Chinese families with Birt-Hogg-Dubé syndrome and provided functional evidence supporting pathogenicity for p.W376R and p.Q44*. The study also offers an early in vitro proof of concept that synthetic FLCN mRNA can restore FLCN expression and normalize mTORC1 signaling, although clinical applicability remains unestablished.
-
Multi-Conformation Targeting of uPAR·uPA
2026-10-05
Khanna and colleagues reported IPR-456, a small molecule identified by screening multiple uPAR conformations generated through molecular dynamics, rather than relying on a single receptor structure. The compound bound uPAR, disrupted uPA recognition, and reduced invasion in MDA-MB-231 breast cancer cells, while its limited effects on migration and adhesion highlighted the biological selectivity and remaining uncertainties of the approach.
-
Deracoxib in Canine Cancer and Inflammation Research
2026-10-04
Deracoxib is a selective COX-2 inhibitor used in veterinary pain and inflammation research and investigated as a possible anticancer agent. In a canine mammary carcinoma cell-line study, deracoxib reduced viability and increased apoptosis, with stronger effects when combined with piroxicam; however, the evidence remains preclinical and does not establish clinical anticancer efficacy.
-
Miltefosine: Signaling Context and Leukopenia Evidence
2026-10-03
Miltefosine is a phospholipid analogue studied across several biological contexts. The strongest supplied evidence concerns neutrophil differentiation and recovery of blood-cell production in cell and irradiation-induced mouse models. This overview compares those findings with vendor-described PI3K/Akt activity, explains the apparent relationship between PI3K/Akt and Ras/MEK/ERK signaling, and defines the major limits on interpretation, including the absence of supplied human efficacy, safety, pharmacokinetic, or comparative clinical evidence.
-
Reactive Oxygen Species Assay Kit: DCFH-DA Guide
2026-10-02
The Reactive Oxygen Species Assay Kit uses a DCFH-DA fluorescent probe to measure ROS-associated oxidation in live cells. Its Rosup positive control and defined storage conditions support reproducible oxidative stress measurement assay workflows, but the fluorescence signal should be interpreted as a relative redox readout rather than a species-specific ROS concentration.
-
IWP-L6: From Wnt Control to Translation
2026-10-01
IWP-L6 offers a high-potency entry point for interrogating Porcn-dependent Wnt biology. This thought-leadership guide connects upstream Wnt maturation to O-GlcNAcylation, glycolysis, osteogenesis, organ development, and translational assay strategy while defining the boundaries of current evidence.
-
Temafloxacin Assay Workflows for Antibacterial Research
2026-10-01
Temafloxacin supports structured MIC mapping, respiratory pathogen profiling, and intracellular mycobacterial assays across a broad concentration range. This guide combines its DNA-targeting mechanism with an orthogonal synergy workflow adapted from a classic oral streptococcal study.
-
QPRT, P2Y11 Signaling, and Breast Cancer Invasion
2026-09-30
Liu et al. identify QPRT as a metabolic enzyme associated with invasive breast cancer and connect its activity to purinergic signaling, Rho–ROCK/PLC–MLCK signaling, and myosin light chain phosphorylation. The study combines expression analysis, genetic perturbation, invasion assays, and pharmacological inhibition to define a testable mechanism linking NAD+ metabolism with cytoskeletal behavior.
-
GLI2–PRDX1 Axis in Bladder Cancer Ferroptosis
2026-09-30
A 2026 Apoptosis study identifies GLI2 as a transcriptional driver of ferroptosis resistance in bladder cancer through PRDX1 upregulation. Its integrated GEO, RNA-sequencing, ChIP, perturbation, rescue, and drug-sensitization experiments position the GLI2–PRDX1 axis as a mechanistic link between tumor progression and cisplatin response.